• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两种常用性能工具的相互转换:对1501例肺癌患者的5844对评估的分析

Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients.

作者信息

Prasad Kuruswamy Thurai, Kaur Harpreet, Muthu Valliappan, Aggarwal Ashutosh Nath, Behera Digambar, Singh Navneet

机构信息

Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.

出版信息

World J Clin Oncol. 2018 Nov 10;9(7):140-147. doi: 10.5306/wjco.v9.i7.140.

DOI:10.5306/wjco.v9.i7.140
PMID:30425939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6230919/
Abstract

AIM

To establish the Karnofsky performance status (KPS) categories which would facilitate the interconversion of the KPS scale to the Eastern Cooperative Oncology Group (ECOG) performance status (PS) scale.

METHODS

This was a retrospective analysis of all patients attending the lung cancer clinic at a tertiary care center over a 5-year period (September 2009 to August 2014). All patients were assessed with both KPS and ECOG PS scales at each visit. Correlation between KPS and ECOG PS was assessed using Spearman's correlation coefficient. KPS categories equivalent to ECOG PS scores were compared using hit rate and weighted kappa (κ).

RESULTS

A total of 1501 patients were assessed over the study period, providing 5844 paired KPS and ECOG PS assessments. The study cohort had a mean (standard deviation; SD) age of 58.4 (10.8) years, with the majority being current or ex-smokers (76.9%) and males (82.3%). Non-small cell lung cancer was the most common histological type ( = 1196, 79.7%) with the majority having advanced (stage IIIB/IV) disease (83.4%). Mean baseline KPS and ECOG PS scores were 77.6 (SD = 14.4) and 1.5 (SD = 1) respectively. The most frequent KPS score was 80 (29%), and the most frequent ECOG PS score was 1 (43%). The overall correlation between KPS and ECOG PS was good (Spearman = -0.84, < 0.0001) but ranged from -0.727 to -0.972 between visits. KPS categories derived from our cohort [10-40 (ECOG 4), 50-60 (ECOG 3), 70 (ECOG 2), 80-90 (ECOG 1), 100 (ECOG 0)] performed better [hit rate 78.1%, κ = 0.749 (0.736-0.762) < 0.0001] than those suggested in the past literature.

CONCLUSION

The current study provides the largest set of paired KPS-ECOG assessments to date. We suggest that the KPS categories 10-40, 50-60, 70, 80-90, and 100 are equivalent to ECOG PS categories of 4, 3, 2, 1, and 0 respectively.

摘要

目的

建立卡氏功能状态(KPS)分类,以促进KPS量表与东部肿瘤协作组(ECOG)功能状态(PS)量表之间的相互转换。

方法

这是一项对一家三级医疗中心肺癌门诊5年期间(2009年9月至2014年8月)所有患者的回顾性分析。所有患者每次就诊时均使用KPS和ECOG PS量表进行评估。使用Spearman相关系数评估KPS和ECOG PS之间的相关性。使用命中率和加权kappa(κ)比较与ECOG PS评分等效的KPS类别。

结果

在研究期间共评估了1501例患者,提供了5844对KPS和ECOG PS评估。研究队列的平均(标准差;SD)年龄为58.4(10.8)岁,大多数为当前或既往吸烟者(76.9%)和男性(82.3%)。非小细胞肺癌是最常见的组织学类型(n = 1196,79.7%),大多数患有晚期(IIIB/IV期)疾病(83.4%)。平均基线KPS和ECOG PS评分分别为77.6(SD = 14.4)和1.5(SD = 1)。最常见的KPS评分为80(29%),最常见的ECOG PS评分为1(43%)。KPS和ECOG PS之间的总体相关性良好(Spearman ρ = -0.84,P < 0.0001),但就诊之间的范围为-0.727至-0.972。从我们的队列中得出的KPS类别[10 - 40(ECOG 4),50 - 60(ECOG 3),70(ECOG 2),80 - 90(ECOG 1),100(ECOG 0)]的表现优于过去文献中建议的类别[命中率78.1%,κ = 0.749(0.736 - 0.762),P < 0.0001]。

结论

本研究提供了迄今为止最大的一组配对KPS - ECOG评估。我们建议KPS类别10 - 40、50 - 60、70、80 - 90和100分别等同于ECOG PS类别4、3、2、1和0。

相似文献

1
Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients.两种常用性能工具的相互转换:对1501例肺癌患者的5844对评估的分析
World J Clin Oncol. 2018 Nov 10;9(7):140-147. doi: 10.5306/wjco.v9.i7.140.
2
Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.卡诺夫斯基和东部肿瘤协作组(ECOG)体能状态评分在肺癌中的应用:一项对来自单一机构的536例患者的前瞻性纵向研究。
Eur J Cancer. 1996 Jun;32A(7):1135-41. doi: 10.1016/0959-8049(95)00664-8.
3
The Functionality Assessment Flowchart (FAF): a new simple and reliable method to measure performance status with a high percentage of agreement between observers.功能评估流程图(FAF):一种新的简单可靠的方法,用于测量功能状态,观察者之间的一致性百分比很高。
BMC Cancer. 2015 Jul 5;15:501. doi: 10.1186/s12885-015-1526-0.
4
Simple prognostic model for patients with advanced cancer based on performance status.基于体能状态的晚期癌症患者简易预后模型
J Oncol Pract. 2014 Sep;10(5):e335-41. doi: 10.1200/JOP.2014.001457. Epub 2014 Aug 12.
5
Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools.将卡氏功能状态评分(KPS)和东部肿瘤协作组功能状态评分(ECOG)转换为姑息治疗功能状态量表(PPS),以及PPS与KPS在预后工具中的互换性。
J Palliat Care. 2013 Autumn;29(3):163-9.
6
Nurse and physician inter-rater agreement of three performance status measures in palliative care outpatients.护士和医生在姑息治疗门诊患者中对三种功能状态测量工具的评定者间一致性。
Support Care Cancer. 2010 May;18(5):609-16. doi: 10.1007/s00520-009-0700-9. Epub 2009 Jul 23.
7
Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer.比较医师和护士的东部肿瘤协作组表现状态(ECOG-PS)评分,以预测癌症患者的临床结局。
Oncologist. 2019 Dec;24(12):e1460-e1466. doi: 10.1634/theoncologist.2018-0882. Epub 2019 Jun 21.
8
Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals.肿瘤医疗专业人员使用东部肿瘤协作组(ECOG)评分对癌症患者进行的体能状态评估。
Case Rep Oncol. 2019 Sep 25;12(3):728-736. doi: 10.1159/000503095. eCollection 2019 Sep-Dec.
9
Inter-rater reliability in performance status assessment among health care professionals: a systematic review.医疗保健专业人员在性能状态评估中的评分者间信度:一项系统评价。
Ann Palliat Med. 2016 Apr;5(2):83-92. doi: 10.21037/apm.2016.03.02.
10
Performance status and survival in cancer patients undergoing palliative care: retrospective study.接受姑息治疗的癌症患者的体能状态与生存情况:回顾性研究
BMJ Support Palliat Care. 2022 Aug 10. doi: 10.1136/spcare-2022-003562.

引用本文的文献

1
[Prehabilitation and enhanced recovery after surgery protocols for head and neck cancer : Value and application of these concepts].[头颈部癌的术前康复与术后强化康复方案:这些概念的价值与应用]
HNO. 2025 Jun;73(6):430-440. doi: 10.1007/s00106-025-01637-w. Epub 2025 May 8.
2
Survival and quality of life after first-time diagnosis of brain metastases: a multicenter, prospective, observational study.首次诊断为脑转移瘤后的生存情况及生活质量:一项多中心、前瞻性、观察性研究。
Lancet Reg Health Eur. 2024 Dec 19;49:101181. doi: 10.1016/j.lanepe.2024.101181. eCollection 2025 Feb.
3
Prognostic Indicators for Precision Treatment of Non-Small Cell Lung Carcinoma.

本文引用的文献

1
Evolving epidemiology of lung cancer in India: Reducing non-small cell lung cancer-not otherwise specified and quantifying tobacco smoke exposure are the key.印度肺癌流行病学的演变:减少非小细胞肺癌(未另行说明)并量化烟草烟雾暴露是关键。
Indian J Cancer. 2017 Jan-Mar;54(1):285-290. doi: 10.4103/ijc.IJC_597_16.
2
Utility of the revised Edmonton Symptom Assessment System (ESAS-r) and the Patient-Reported Functional Status (PRFS) in lung cancer patients.修订后的埃德蒙顿症状评估系统(ESAS-r)和患者报告的功能状态(PRFS)在肺癌患者中的应用。
Support Care Cancer. 2018 Mar;26(3):767-775. doi: 10.1007/s00520-017-3887-1. Epub 2017 Oct 12.
3
非小细胞肺癌精准治疗的预后指标。
Cells. 2024 Oct 28;13(21):1785. doi: 10.3390/cells13211785.
4
Reliability and Validity of the Tagalog Version of the FACIT-Pal-14 Instrument in Measuring the Quality of Life of Filipino Cancer Patients.FACIT-Pal-14量表他加禄语版本在测量菲律宾癌症患者生活质量方面的信度和效度
Acta Med Philipp. 2024 Jun 14;58(10):5-13. doi: 10.47895/amp.vi0.7804. eCollection 2024.
5
Therapeutic vaccines for advanced non-small cell lung cancer.晚期非小细胞肺癌的治疗性疫苗。
Cochrane Database Syst Rev. 2024 Mar 12;3(3):CD013377. doi: 10.1002/14651858.CD013377.pub2.
6
Prognostic Effect of Performance Status on Outcomes of Patients with Colorectal Cancer Receiving First-Line Chemotherapy: A Meta-analysis.体能状态对接受一线化疗的结直肠癌患者结局的预后影响:一项荟萃分析。
J Gastrointest Cancer. 2024 Mar;55(1):418-426. doi: 10.1007/s12029-023-00983-8. Epub 2023 Nov 15.
7
Health Outcomes with Curative and Palliative Therapies in Real World: Role of the Quality of Life Summary Score in Thoracic Oncology Patients.现实世界中根治性和姑息性治疗的健康结局:生活质量总评分在胸部肿瘤患者中的作用
Cancers (Basel). 2023 Jul 27;15(15):3821. doi: 10.3390/cancers15153821.
8
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.用于预测和评估接受纳武单抗或帕博利珠单抗治疗的晚期非小细胞肺癌患者预后的帕特雷免疫治疗评分模型的验证:一项欧洲多中心研究的结果
Ther Adv Med Oncol. 2022 Sep 8;14:17588359221122728. doi: 10.1177/17588359221122728. eCollection 2022.
9
Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters.非小细胞肺癌中程序性死亡配体1的表达及肿瘤浸润淋巴细胞:与临床病理参数的关联
J Pathol Transl Med. 2021 Nov;55(6):398-405. doi: 10.4132/jptm.2021.08.08. Epub 2021 Oct 6.
10
Enteral Nutrition Combined with Improved-Sijunzi Decoction Shows Positive Effect in Precachexia Cancer Patients: A Retrospective Analysis.肠内营养联合改良四君子汤对癌前恶病质患者显示出积极效果:一项回顾性分析
Evid Based Complement Alternat Med. 2021 Sep 22;2021:7357521. doi: 10.1155/2021/7357521. eCollection 2021.
Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B and Folate Supplementation in Nonsquamous, Non-Small-cell Lung Cancer Patients Undergoing First-line Pemetrexed-based Chemotherapy.
PEMVITASTART研究的原理与设计——一项开放性随机试验,比较非鳞状非小细胞肺癌患者在接受一线培美曲塞化疗时同时补充维生素B和叶酸与标准补充方式的效果
Clin Lung Cancer. 2017 Jul;18(4):432-435. doi: 10.1016/j.cllc.2016.11.017. Epub 2016 Dec 2.
4
Prevalence of low body mass index among newly diagnosed lung cancer patients in North India and its association with smoking status.印度北部新诊断肺癌患者中低体重指数的流行情况及其与吸烟状况的关系。
Thorac Cancer. 2011 Feb;2(1):27-31. doi: 10.1111/j.1759-7714.2010.00037.x.
5
Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.使用查尔森合并症指数和简化合并症评分进行合并症评估及其与肺癌一线化疗期间临床结局的关联
Clin Lung Cancer. 2016 May;17(3):205-213.e1. doi: 10.1016/j.cllc.2015.10.002. Epub 2015 Oct 22.
6
Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy.非鳞状非小细胞肺癌患者一线培美曲塞化疗期间分级补充叶酸与总血浆同型半胱氨酸水平与血液学毒性的相关性
Am J Clin Oncol. 2017 Feb;40(1):75-82. doi: 10.1097/COC.0000000000000111.
7
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.多西他赛联合尼达尼布对比多西他赛联合安慰剂治疗既往治疗的非小细胞肺癌(LUME-Lung 1):一项 III 期、双盲、随机对照试验。
Lancet Oncol. 2014 Feb;15(2):143-55. doi: 10.1016/S1470-2045(13)70586-2. Epub 2014 Jan 9.
8
Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools.将卡氏功能状态评分(KPS)和东部肿瘤协作组功能状态评分(ECOG)转换为姑息治疗功能状态量表(PPS),以及PPS与KPS在预后工具中的互换性。
J Palliat Care. 2013 Autumn;29(3):163-9.
9
Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation.卡氏功能状态评估及一种简单评估算法系统的提议。
BMC Med Inform Decis Mak. 2013 Jul 19;13:72. doi: 10.1186/1472-6947-13-72.
10
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.重点:培美曲塞维持治疗对比安慰剂用于培美曲塞联合顺铂诱导治疗后晚期非鳞状非小细胞肺癌的 III 期研究的最终总生存结果。
J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8.